The 5 1 receptor is a prototypical G protein-coupled receptor (GPCR) that plays diverse roles in both the central nervous system and peripheral vasculature. In the central nervous system these receptors are widely distributed, being expressed in the neocortex, claustrum, mammilary nuclei, basal ganglia, and anterior cingulate cortex (1). 5-HT 2A receptors are also highly expressed in vascular smooth muscle and renal mesangial cells, where they mediate contraction and proliferation (2-4), and platelets, where they contribute to aggregation and adherence (5), as well as in kidney (6) and skeletal muscle (7,8). The heterogeneous expression of the 5-HT 2A receptor is accompanied by a diverse array of pathophysiological implications for 5-HT 2A receptor signaling, including roles in sleep, hallucinogenesis, schizophrenia, appetite control, neuroendocrine secretions, hypertension, and depression (9 -12). The 5-HT 2A receptor is involved in the mechanism of action of hallucinogens, atypical neuroleptics, antidepressants, and other psychoactive drugs.5-HT 2A receptors signal primarily through heterotrimeric proteins of the G q/11 subfamily to the activation of phospholipase C, and the subsequent formation of diacylglycerol and activation of protein kinase C (13-15). Other second messengers and effectors regulated by the 5-HT 2A receptor include phospholipase A 2 (16 -18), phospholipase D (19), Ca 2ϩ channels (20 -22), reactive oxygen and nitrogen species (23, 24), and Na ϩ /H ϩ exchange (25,26). In essentially all cases, activation of downstream signaling molecules has been shown to be mediated by heterotrimeric G proteins.Calmodulin (CaM) is a small (148 amino acids, ϳ17 kDa), soluble protein, which functions as the major calcium sensor in most cells (27). As a prototypical member of the EF-hand family of Ca 2ϩ -binding proteins, CaM can bind up to four Ca 2ϩ ions, which subsequently extend the protein to expose hydrophobic patches capable of binding cellular targets (28,29). These targets number well over one hundred and include enzymes, ion channels, transcription factors, and cytoskeletal proteins. Recently, CaM has been shown to bind to several plasma membrane receptors, including the epidermal growth factor receptor, platelet glycoprotein VI, and some GPCRs (30, 31). The first GPCR that was shown to interact with CaM was the metabotropic glutamate subtype 5 receptor, which contains a * This work was supported by Department of Veterans Affairs Merit and Research Enhancement Award Program awards (to J. R. R.), by National Institutes of Health Grants GM08716 (to J. H. T.) and DK52448 and GM63909 (to J. R. R.), by a predoctoral fellowship from the American Heart Association, Mid-Atlantic Affiliate (Grant 0215195U to J. H. T.), and by laboratory endowments jointly supported by the Medical University of South Carolina, Division of Nephrology and Dialysis Clinics, Inc. (to J. R. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked...